At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 19 enrolled
Drug / intervention
amphotericin B in 30% DMSO +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study
In Brief
A Phase 4 clinical trial evaluating amphotericin B in 30% DMSO and 30% DMSO for Fungal Infection and 2 related conditions. Completed, enrolled 19 participants across 1 site.
Detailed Summary
The randomized control trial study aimed to evaluate effectiveness and safety of amphotericin B in 30% DMSO solution comparing with 30% DMSO solution in NDMs onychomycosis treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFungal Infection, Onychomycosis, Fungus, Nail
CountriesThailand
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedJan 2019
Primary CompletionNov 2020
Study CompletionNov 2020
TodayJul 2026
First PostedJan 24, 2019
Enrollment StartJan 15, 2019
Primary CompletionNov 15, 2020
Study CompletionNov 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.4 years ago
Interventions
amphotericin B in 30% DMSOdrug
amphotericin B in 30% DMSO was given to patients in active comparators group for continuous 12 weeks.
30% DMSOdrug
30% DMSO was given to patients in placebo comparators group for continuous 12 weeks.